[CAS NO. 127294-70-6] Balofloxacin
PRODUCTS SPECIFICATIONS [127294-70-6]
DESCRIPTION [127294-70-6]
Overview
| MDL | MFCD00864925 |
|---|---|
| Molecular Weight | 389.42 |
| Molecular Formula | C20H24FN3O4 |
| SMILES | O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CC(NC)CCC4)=C3OC)C1=O)O |
Summary
Balofloxacin (Q-35) is an orally active fluoroquinolone antibiotic with broad-spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. Balofloxacin can be used for the research of respiratory, intestinal, and urinary tract infections [1] [2] .
IC50 & Target
|
Quinolone |
In Vitro
Balofloxacin (25 mg/mL; 1 h) decreases the growth of S.
aureus
that adhered to human corneal epithelial cells (HCECs)
[2]
.
Balofloxacin inhibits the S.
aureus
ATCC 25923, with a MIC of 0.125 mg/mL
[2]
.
Balofloxacin (0.05-500 μg/mL; 72 h) does not induce toxicity on the HCECs at a low concentration, such as 0.625 mg/mL
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Balofloxacin (200 mg/kg/day; p.o. for 5 d) reduces the counts of viable
M. pneumonia
in the lungs of hamsters
[3]
.
Balofloxacin eye drops (0.5%) is effective in S. aureus bacterial keratitis of rabbits
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 0.67 mg/mL ( 1.72 mM ; Need ultrasonic)
DMSO : 0.67 mg/mL ( 1.72 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5679 mL | 12.8396 mL | 25.6792 mL |
| 5 mM | --- | --- | --- |
| 10 mM | --- | --- | --- |
References
- [1] Alksne L. Balofloxacin Choongwae. Curr Opin Investig Drugs. 2003 Feb;4(2):224-9.
- [2] Jiang H, et, al. In vitro and in vivo effectiveness evaluation of balofloxacin in experimental Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2014 Aug;30(6):482-8.
- [3] Gohara Y, et, al. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumonia. Antimicrob Agents Chemother. 1993 Sep;37(9):1826-30.
Synonyms
